Circulating GRP78 antibodies from ovarian cancer patients: a promising tool for cancer cell targeting drug delivery system?

Article Article scientifique Article Circulating GRP78 antibodies from ovarian cancer patients: a promising tool for cancer cell targeting drug delivery system? fre 2017 author Van Hoesen Kylie 842417 author Meynier Sonia 780179 author Ribaux Pascale Garlonne 543255 author Petignat Patrick 586685 author Delie Salmon Florence 121330 author Cohen Marie-Benoîte 0000-0003-4621-5464 135615 10.18632/oncotarget.22412 1949-2553 http://www.oncotarget.com/fulltext/22412 Glucose-regulated protein 78 (GRP78) is a chaperone protein that has a high frequency in tumor cells. Normally it is found in the endoplasmic reticulum to assist in protein folding, but under cellular stress, GRP78 influences proliferative signaling pathways at the cell surface. The increased expression elicits autoantibody production, providing a biomarker of ovarian cancer, as well as other types of cancer. This study aims to determine the epitope recognition of GRP78 autoantibodies isolated from serum of ovarian cancer patients and use the identified antibodies to design new drug delivery systems to specifically target cancer cells. We first confirmed that the membrane GRP78 levels are increased in ovarian cancer cells and positively correlate with proliferation. However, the level of circulating GRP78 autoantibodies did not correlate with membrane GRP78 expression in ovarian cancer cells and was lower, although not significantly, compared to control patients. We then determined the epitope recognition of GRP78 autoantibodies and showed that treatment with paclitaxel-loaded nanoparticles coated with anti-GRP78 antibodies significantly decreased tumor development in chick embryo culture of ovarian cancer cell tumors compared to paclitaxel treatment alone. This evidence suggests that nanoparticle drug delivery systems coupled with antibodies against GRP78 has potential as a powerful therapy against ovarian cancer. Dewey 615 Dewey 618 31 Section des sciences pharmaceutiques 17 58 Département de pédiatrie, gynécologie et obstétrique 223 false 584 Laboratoire de biologie des tumeurs gynécologiques et du développement 927 590 Prévention du cancer du col utérin 933 Oncotarget 31be3dea-f18f-4a62-b00c-aa01680134de Article (Published version) Public Oncotarget.pdf 3100550 application/pdf openAccess Faculté des sciences / Section des sciences pharmaceutiques Faculté de médecine / Section de médecine clinique / Département de pédiatrie, gynécologie et obstétrique

Title	Published in	Year	Views	Downloads

Circulating GRP78 antibodies from ovarian cancer patients: a promising tool for cancer cell targeting drug delivery system?	Oncotarget	2017	637	243
The Dark Side of Cell Fusion	International journal of molecular sciences	2016	581	349

Archive ouverte UNIGE

Van Hoesen, Kylie